133 related articles for article (PubMed ID: 35728293)
1. Heterocyclic ring expansion yields anthraquinone derivatives potent against multidrug resistant tumor cells.
Tikhomirov AS; Tsvetkov VB; Volodina YL; Litvinova VA; Andreeva DV; Dezhenkova LG; Kaluzhny DN; Treshalin ID; Shtil AA; Shchekotikhin AE
Bioorg Chem; 2022 Oct; 127():105925. PubMed ID: 35728293
[TBL] [Abstract][Full Text] [Related]
2. Amides of pyrrole- and thiophene-fused anthraquinone derivatives: A role of the heterocyclic core in antitumor properties.
Tikhomirov AS; Litvinova VA; Andreeva DV; Tsvetkov VB; Dezhenkova LG; Volodina YL; Kaluzhny DN; Treshalin ID; Schols D; Ramonova AA; Moisenovich MM; Shtil AA; Shchekotikhin AE
Eur J Med Chem; 2020 Aug; 199():112294. PubMed ID: 32428792
[TBL] [Abstract][Full Text] [Related]
3. Thiophene-2-carboxamide derivatives of anthraquinone: A new potent antitumor chemotype.
Volodina YL; Tikhomirov AS; Dezhenkova LG; Ramonova AA; Kononova AV; Andreeva DV; Kaluzhny DN; Schols D; Moisenovich MM; Shchekotikhin AE; Shtil AA
Eur J Med Chem; 2021 Oct; 221():113521. PubMed ID: 34082225
[TBL] [Abstract][Full Text] [Related]
4. Novel curcumin derivatives as P-glycoprotein inhibitors: Molecular modeling, synthesis and sensitization of multidrug resistant cells to doxorubicin.
Sagnou M; Novikov FN; Ivanova ES; Alexiou P; Stroylov VS; Titov IY; Tatarskiy VV; Vagida MS; Pelecanou M; Shtil AA; Chilov GG
Eur J Med Chem; 2020 Jul; 198():112331. PubMed ID: 32403017
[TBL] [Abstract][Full Text] [Related]
5. New anthra[2,3-b]furancarboxamides: A role of positioning of the carboxamide moiety in antitumor properties.
Volodina YL; Dezhenkova LG; Tikhomirov AS; Tatarskiy VV; Kaluzhny DN; Moisenovich AM; Moisenovich MM; Isagulieva AK; Shtil AA; Tsvetkov VB; Shchekotikhin AE
Eur J Med Chem; 2019 Mar; 165():31-45. PubMed ID: 30659997
[TBL] [Abstract][Full Text] [Related]
6. Anthrapyridones, a novel group of antitumour non-cross resistant anthraquinone analogues. Synthesis and molecular basis of the cytotoxic activity towards K562/DOX cells.
Tarasiuk J; Stefańska B; Plodzich I; Tkaczyk-Gobis K; Seksek O; Martelli S; Garnier-Suillerot A; Borowski E
Br J Pharmacol; 2002 Mar; 135(6):1513-23. PubMed ID: 11906965
[TBL] [Abstract][Full Text] [Related]
7. New antitumor anthra[2,3-b]furan-3-carboxamides: Synthesis and structure-activity relationship.
Tikhomirov AS; Lin CY; Volodina YL; Dezhenkova LG; Tatarskiy VV; Schols D; Shtil AA; Kaur P; Chueh PJ; Shchekotikhin AE
Eur J Med Chem; 2018 Mar; 148():128-139. PubMed ID: 29459273
[TBL] [Abstract][Full Text] [Related]
8. Discovery of antitumor anthra[2,3-b]furan-3-carboxamides: Optimization of synthesis and evaluation of antitumor properties.
Shchekotikhin AE; Dezhenkova LG; Tsvetkov VB; Luzikov YN; Volodina YL; Tatarskiy VV; Kalinina AA; Treshalin MI; Treshalina HM; Romanenko VI; Kaluzhny DN; Kubbutat M; Schols D; Pommier Y; Shtil AA; Preobrazhenskaya MN
Eur J Med Chem; 2016 Apr; 112():114-129. PubMed ID: 26890118
[TBL] [Abstract][Full Text] [Related]
9. Role of structural factors of antitumour anthraquinone derivatives and analogues in the ability to undergo bioreductive activation by NADPH cytochrome P450 reductase: implications for increasing the activity against sensitive and multidrug-resistant leukaemia HL60 cells.
Kostrzewa-Nowak D; Bieg B; Paine MJ; Wolf CR; Tarasiuk J
Anticancer Drugs; 2012 Apr; 23(4):393-405. PubMed ID: 22205152
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of 7-oxo-7H-naphtho[1,2,3-de]quinoline derivatives as potential anticancer agents active on multidrug resistant cell lines.
Dzieduszycka M; Bontemps-Gracz MM; Stefańska B; Martelli S; Piwkowska A; Arciemiuk M; Borowski E
Bioorg Med Chem; 2006 May; 14(9):2880-6. PubMed ID: 16458007
[TBL] [Abstract][Full Text] [Related]
11. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E
Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123
[TBL] [Abstract][Full Text] [Related]
12. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
[TBL] [Abstract][Full Text] [Related]
13. HOXB4 knockdown reverses multidrug resistance of human myelogenous leukemia K562/ADM cells by downregulating P-gp, MRP1 and BCRP expression via PI3K/Akt signaling pathway.
Wang H; Jia XH; Chen JR; Yi YJ; Wang JY; Li YJ; Xie SY
Int J Oncol; 2016 Dec; 49(6):2529-2537. PubMed ID: 27779650
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic effect of the cyclosporin PSC 833 in multidrug-resistant leukaemia cells with increased expression of P-glycoprotein.
Lehne G; Rugstad HE
Br J Cancer; 1998 Sep; 78(5):593-600. PubMed ID: 9744497
[TBL] [Abstract][Full Text] [Related]
15. BME, a novel compound of anthraquinone, down regulated P-glycoprotein expression in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells via generation of reactive oxygen species.
Wang J; Liu L; Cen J; Ji B
Chem Biol Interact; 2015 Sep; 239():139-45. PubMed ID: 26169035
[TBL] [Abstract][Full Text] [Related]
16. Design, Synthesis, Molecular Docking, and Biological Evaluation of New Emodin Anthraquinone Derivatives as Potential Antitumor Substances.
Li Y; Guo F; Chen T; Zhang L; Wang Z; Su Q; Feng L
Chem Biodivers; 2020 Sep; 17(9):e2000328. PubMed ID: 32627416
[TBL] [Abstract][Full Text] [Related]
17. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
[TBL] [Abstract][Full Text] [Related]
18. 5-Oxo-hexahydroquinoline Derivatives and Their Tetrahydroquinoline Counterparts as Multidrug Resistance Reversal Agents.
Shahraki O; Khoshneviszadeh M; Dehghani M; Mohabbati M; Tavakkoli M; Saso L; Edraki N; Firuzi O
Molecules; 2020 Apr; 25(8):. PubMed ID: 32316291
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of novel bis-anthraquinone derivatives and their biological evaluation as antitumor agents.
Taher AT; Hegazy GH
Arch Pharm Res; 2013 May; 36(5):573-8. PubMed ID: 23471561
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of Strychnos alkaloids as MDR reversal agents for cancer cell eradication.
Munagala S; Sirasani G; Kokkonda P; Phadke M; Krynetskaia N; Lu P; Sharom FJ; Chaudhury S; Abdulhameed MD; Tawa G; Wallqvist A; Martinez R; Childers W; Abou-Gharbia M; Krynetskiy E; Andrade RB
Bioorg Med Chem; 2014 Feb; 22(3):1148-55. PubMed ID: 24405813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
